Agios Pharmaceuticals Stock

Agios Pharmaceuticals Dividend 2024

Agios Pharmaceuticals Dividend

0 USD

Agios Pharmaceuticals Dividend yield

Ticker

AGIO

ISIN

US00847X1046

WKN

A1W2RM

How much dividend does Agios Pharmaceuticals 2024 pay?

According to the latest status from September 2024, Agios Pharmaceuticals paid a total of 0 USD per share in dividends within the last 12 months. With the current Agios Pharmaceuticals price of 46.55 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Agios Pharmaceuticals Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Agios Pharmaceuticals Dividend Safe?

Agios Pharmaceuticals has been increasing the dividend for 0 years.

Over the past 10 years, Agios Pharmaceuticals has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Agios Pharmaceuticals's Dividend Distributions

Agios Pharmaceuticals’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Agios Pharmaceuticals's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Agios Pharmaceuticals's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Agios Pharmaceuticals’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Agios Pharmaceuticals Aktienanalyse

What does Agios Pharmaceuticals do?

Agios Pharmaceuticals Inc. is a US biopharmaceutical company specializing in the development of treatment options for rare genetic disorders and cancer. The company was founded in 2008 by David Schenkein, Lewis Cantley, and Tak Mak and is headquartered in Cambridge, Massachusetts. The history of Agios Pharmaceuticals Inc. began with the discovery of IDH1 mutations, which are frequently found in many types of cancer. The founders of Agios recognized the significance of this discovery and laid the foundation for the development of drugs targeting this mutation. Agios' business model is to develop innovative therapeutics for diseases that are often neglected by other companies. The company focuses on researching enzymes that play important roles in genetic disorders and cancer processes. Agios collaborates closely with other companies and research institutions to quickly translate its research findings into clinical research and subsequent patient treatment. Additionally, the company has established itself as a pioneer in the application of artificial intelligence in drug development in recent years. Agios divides its portfolio into two main areas: oncology and rare genetic disorders. In oncology, the company utilizes targeted therapies based on a deep understanding of the underlying cancer biology. Therapeutic approaches include enzyme inhibitors, immunotherapies, and cell therapies. Agios has several promising candidates in clinical development in this area, including Idhifa for the treatment of acute myeloid leukemia, as well as Ivosidenib and Ag-120, both used to treat brain tumors. In the field of rare genetic disorders, Agios specializes in a group of enzyme defects known as citric acid cycle disorders. Agios is the only provider of drugs targeting these enzymes. The company recently received approval for Tibsovo for the treatment of acute myeloid leukemia in the United States. Agios aims to continuously expand its pipeline of therapeutics to meet the unmet need for treatments for rare diseases and cancer. The company has an extensive research pipeline, with several drugs in preclinical and clinical development. Agios works closely with other companies and research institutions to quickly translate its research findings into clinical development and subsequent patient treatment. Overall, Agios Pharmaceuticals has made impressive strides in recent years and has established itself as a key player in the biopharmaceutical industry. The company specializes in developing innovative therapies for rare genetic disorders and cancer and collaborates closely with other companies and research institutions. With its extensive research pipeline and the application of artificial intelligence, Agios is well-positioned to contribute to the development of new therapeutic options in the future. Agios Pharmaceuticals is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Agios Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Frequently Asked Questions about Agios Pharmaceuticals stock

How much dividend does Agios Pharmaceuticals pay?

Over the past 12 months, Agios Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agios Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Agios Pharmaceuticals?

The current dividend yield of Agios Pharmaceuticals is .

When does Agios Pharmaceuticals pay dividends?

Agios Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Agios Pharmaceuticals?

Agios Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Agios Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Agios Pharmaceuticals located?

Agios Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Agios Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Agios Pharmaceuticals from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Agios Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Agios Pharmaceuticals in the year 2023?

In the year 2023, Agios Pharmaceuticals distributed 0 USD as dividends.

In which currency does Agios Pharmaceuticals pay out the dividend?

The dividends of Agios Pharmaceuticals are distributed in USD.

Andere Kennzahlen von Agios Pharmaceuticals

Our stock analysis for Agios Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agios Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.